StockUS listing USCGONNASDAQHealthcareProfitless Growth

CG Oncology, Inc. Common stock(CGON) Stock Analysis | Healthcare

USD --+0.00%
Reward49Moderate
Risk24Low
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 7.10Bn
Reward Ratingⓘ49 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ24 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CGON to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CG Oncology, Inc. Common stock?

, a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

AI Brief Pro

The brief on CG Oncology, Inc. Common stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CG Oncology, Inc. Common stock?

, a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 7.10B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (49)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.349
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
43,000 shares
$227k
233,751.32 shares
$2.7M
3-6months
839,129 shares
$2.8M
1371,085 shares
$24.8M
6-9months
317,564 shares
$1.3M
0
9-12months
211,145 shares
$585k
0